This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data

MOUNTAIN VIEW, Calif. ( TheStreet) -- An experimental ChemoCentryx (CCXI) drug designed to treat kidney damage caused by diabetes doesn't appear to be working very well, according to an interim analysis of an mid-stage study announced Tuesday.

ChemoCentryx intends to continue the diabetic nephropathy drug study until final data are available in the second half of next year, but doubts about its success caused the company's stock to shed 19% to $6.66 in Tuesday trading.

Late last month, a different ChemoCentryx drug failed a phase III study in Crohn's disease.

ChemoCentryx is conducting a 52-week study of two different doses of CCX140 compared to a placebo in patients with diabetic nephropathy. The interim analysis disclosed Tuesday examined efficacy and safety after 12 weeks of dosing. During an August conference call with investors, ChemoCentryx said a reduction in proteinuria (protein levels in the kidneys) of 20% or more would define success for CCX140 in the interim analysis.

CCX140 was unable to hit that 20% proteinuria reduction target.

After 12 weeks of treatment, patients on the 5 mg dose of CCX140 showed a 21% reduction in proteinuria compared to a 12% reduction for patients on placebo. The difference was not statistically significant.

A higher 10 mg dose of CCX140 performed worse than placebo, demonstrating a 9% reduction in proteinuria after 12 weeks, according to ChemoCentryx.

ChemoCentryx said certain subsets of patients -- defined before the study began -- did show reductions in proteinuria greater than 30% following treatment with CCX140 compared to placebo.

These data "support the continued progress of full 52 weeks of dosing in the phase II trial as planned," the company said, in a statement.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CCXI $2.41 -1.20%
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs